AG017 / Genten Therap, Precigen - LARVOL DELTA

ActoBio Therapeutics receives IND green light for new antigen-specific immunotherapy study aimed at improving celiac patients' tolerance of gluten (PRNewswire) - "ActoBio Therapeutics, Inc....announced that the U.S. Food and Drug Administration (FDA) has given its permission to an Investigational New Drug (IND) application for AG017, an innovative orally-delivered therapeutic candidate for the treatment of celiac disease. ActoBio Therapeutics™ plans to enroll celiac disease patients in the Phase Ib/IIa study in the U.S. and Europe later this year....We have demonstrated that this product is safe and efficacious in animal studies."

IND • New P1/2 trial